Name (Synonyms) | Correlation | |
---|---|---|
drug1054 | Exposure: Covid-19 infection Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003251 | Male infertility HPO | 1.00 |
HP:0000789 | Infertility HPO | 0.38 |
There is one clinical trial.
Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.
Description: Sperm concentration (x10^6/ml) between case and control group.
Measure: Semen parameters Time: 3 visits (up to 75 days apart)Description: Sperm Motility (%) between case and control group.
Measure: Sperm Parameters Time: 3 visits (up to 75 days apart)Description: Sperm normal morphology (%) between case and control group.
Measure: Sperm Parameters Time: 3 visits (up to 75 days apart)Description: Testosterone (nmol/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Follicle Stimulating Hormone(IU/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Luteinising hormone(IU/L) between case and control group.
Measure: Hormones measurement Time: 3 visits (up to 75 days apart)Description: Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.
Measure: Seminal Reactive oxygen species Time: 3 visits (up to 75 days apart)Description: Compare Sperm DNA fragmentation rate (%) between case and control group.
Measure: Sperm DNA fragmentation rate Time: 3 visits (up to 75 days apart)